The Pharmaceutical Journal
Vol 272 No 7298 p566
8 May 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Data presented on new semi-synthetic antibiotic

The lead compound of a new class of antibiotics, called BAY 73-7388, has demonstrated potent in vivo and in vitro activity against resistant bacteria, according to data presented jointly by researchers for Bayer and Paratek at the European Congress of Clinical Microbiology and Infectious Diseases in Prague this week.

BAY 73-7388 is a semi-synthetic antibiotic compound for intravenous use, from a class of antibiotics called aminomethylcyclines.

Pre-clinical research has also shown that the compound did not demonstrate cross-resistance to current antibiotics.